These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

200 related articles for article (PubMed ID: 23298957)

  • 1. Perspective: nonalcoholic fatty liver disease and cardiovascular risk.
    Nestel PJ; Mensink RP
    Curr Opin Lipidol; 2013 Feb; 24(1):1-3. PubMed ID: 23298957
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Alanine aminotransferase as a marker of non-alcoholic fatty liver disease in relation to type 2 diabetes mellitus and cardiovascular disease.
    Schindhelm RK; Diamant M; Dekker JM; Tushuizen ME; Teerlink T; Heine RJ
    Diabetes Metab Res Rev; 2006; 22(6):437-43. PubMed ID: 16832839
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The central role of the non alcoholic fatty liver disease in metabolic syndrome.
    Hurjui DM; Niţă O; Graur LI; Mihalache L; Popescu DS; Graur M
    Rev Med Chir Soc Med Nat Iasi; 2012; 116(2):425-31. PubMed ID: 23077931
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Risk of severe liver disease in nonalcoholic fatty liver disease with normal aminotransferase levels: a role for insulin resistance and diabetes.
    Fracanzani AL; Valenti L; Bugianesi E; Andreoletti M; Colli A; Vanni E; Bertelli C; Fatta E; Bignamini D; Marchesini G; Fargion S
    Hepatology; 2008 Sep; 48(3):792-8. PubMed ID: 18752331
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Nonalcoholic fatty liver disease and vascular risk.
    Bhatia LS; Curzen NP; Byrne CD
    Curr Opin Cardiol; 2012 Jul; 27(4):420-8. PubMed ID: 22596186
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Nonalcoholic fatty liver is not associated with carotid intima-media thickness in type 2 diabetic patients.
    Petit JM; Guiu B; Terriat B; Loffroy R; Robin I; Petit V; Bouillet B; Brindisi MC; Duvillard L; Hillon P; Cercueil JP; Verges B
    J Clin Endocrinol Metab; 2009 Oct; 94(10):4103-6. PubMed ID: 19584186
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The role of non-alcoholic fatty liver disease in cardiovascular disease.
    Perseghin G
    Dig Dis; 2010; 28(1):210-3. PubMed ID: 20460913
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Molecular mechanisms of steatosis in nonalcoholic fatty liver disease.
    Pettinelli P; Obregón AM; Videla LA
    Nutr Hosp; 2011; 26(3):441-50. PubMed ID: 21892559
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The interactions of nonalcoholic fatty liver disease and cardiovascular diseases.
    Perazzo H; Poynard T; Dufour JF
    Clin Liver Dis; 2014 Feb; 18(1):233-48. PubMed ID: 24274877
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pathology of nonalcoholic fatty liver disease.
    Yeh MM; Brunt EM
    Am J Clin Pathol; 2007 Nov; 128(5):837-47. PubMed ID: 17951208
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Nonalcoholic fatty liver disease and the metabolic syndrome: clinical implications and treatment.
    Rahimi RS; Landaverde C
    Nutr Clin Pract; 2013 Feb; 28(1):40-51. PubMed ID: 23286927
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Non-alcoholic fatty liver disease, the metabolic syndrome and the risk of cardiovascular disease: the plot thickens.
    Targher G
    Diabet Med; 2007 Jan; 24(1):1-6. PubMed ID: 17227317
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Nonalcoholic fatty liver disease in HIV-infected patients referred to a metabolic clinic: prevalence, characteristics, and predictors.
    Guaraldi G; Squillace N; Stentarelli C; Orlando G; D'Amico R; Ligabue G; Fiocchi F; Zona S; Loria P; Esposito R; Palella F
    Clin Infect Dis; 2008 Jul; 47(2):250-7. PubMed ID: 18532884
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Liver enzymes, nonalcoholic fatty liver disease, and incident cardiovascular disease: a narrative review and clinical perspective of prospective data.
    Ghouri N; Preiss D; Sattar N
    Hepatology; 2010 Sep; 52(3):1156-61. PubMed ID: 20658466
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Non-alcoholic fatty liver disease (NAFLD) and cardiovascular disease: an open question.
    Loria P; Lonardo A; Bellentani S; Day CP; Marchesini G; Carulli N
    Nutr Metab Cardiovasc Dis; 2007 Nov; 17(9):684-98. PubMed ID: 17560098
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The metabolic syndrome and nonalcoholic fatty liver disease.
    Collantes RS; Ong JP; Younossi ZM
    Panminerva Med; 2006 Mar; 48(1):41-8. PubMed ID: 16633331
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Endothelial dysfunction and cardiovascular risk profile in nonalcoholic fatty liver disease.
    Villanova N; Moscatiello S; Ramilli S; Bugianesi E; Magalotti D; Vanni E; Zoli M; Marchesini G
    Hepatology; 2005 Aug; 42(2):473-80. PubMed ID: 15981216
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Persistent elevation of liver function enzymes within the reference range is associated with increased cardiovascular risk in young adults: the Bogalusa Heart Study.
    Patel DA; Srinivasan SR; Xu JH; Chen W; Berenson GS
    Metabolism; 2007 Jun; 56(6):792-8. PubMed ID: 17512312
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Ectopic fat, insulin resistance, and nonalcoholic fatty liver disease: implications for cardiovascular disease.
    Byrne CD; Targher G
    Arterioscler Thromb Vasc Biol; 2014 Jun; 34(6):1155-61. PubMed ID: 24743428
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The epidemiology of nonalcoholic fatty liver disease in adults.
    Clark JM
    J Clin Gastroenterol; 2006 Mar; 40 Suppl 1():S5-10. PubMed ID: 16540768
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.